0001415889-24-019797.txt : 20240718 0001415889-24-019797.hdr.sgml : 20240718 20240718200514 ACCESSION NUMBER: 0001415889-24-019797 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240718 FILED AS OF DATE: 20240718 DATE AS OF CHANGE: 20240718 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GC Corp. CENTRAL INDEX KEY: 0001931382 ORGANIZATION NAME: STATE OF INCORPORATION: M5 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-42179 FILM NUMBER: 241125805 BUSINESS ADDRESS: STREET 1: 107 IHYEON-RO,30BEON-GIL STREET 2: GILHEUNG-GU, YONGIN-SI CITY: GYEONGGI-DO STATE: M5 ZIP: 16924 BUSINESS PHONE: 82-31-260-9300 MAIL ADDRESS: STREET 1: 107 IHYEON-RO,30BEON-GIL STREET 2: GILHEUNG-GU, YONGIN-SI CITY: GYEONGGI-DO STATE: M5 ZIP: 16924 FORMER NAME: FORMER CONFORMED NAME: Green Cross Holdings Corp DATE OF NAME CHANGE: 20220526 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GC Cell Corp CENTRAL INDEX KEY: 0001931891 ORGANIZATION NAME: STATE OF INCORPORATION: M5 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-42179 FILM NUMBER: 241125804 BUSINESS ADDRESS: STREET 1: 107 IHYEON-RO, 30BEON-GIL STREET 2: GILHEUNG-GU, YONGIN-SI CITY: GYEONGGI-DO STATE: M5 ZIP: 16924 BUSINESS PHONE: 82-31-260-9300 MAIL ADDRESS: STREET 1: 107 IHYEON-RO, 30BEON-GIL STREET 2: GILHEUNG-GU, YONGIN-SI CITY: GYEONGGI-DO STATE: M5 ZIP: 16924 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Artiva Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001817241 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 863614316 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5505 MOREHOUSE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 267-4467 MAIL ADDRESS: STREET 1: 5505 MOREHOUSE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 3 1 form3-07192024_120709.xml X0206 3 2024-07-18 0 0001817241 Artiva Biotherapeutics, Inc. ARTV 0001931382 GC Corp. 107 IHYEON-RO,30BEON-GIL GILHEUNG-GU, YONGIN-SI GYEONGGI-DO M5 16924 KOREA, REPUBLIC OF false false true false 0001931891 GC Cell Corp 107 IHYEON-RO, 30BEON-GIL GIHEUNG-GU, YONGIN-S GYEONGGI-DO, M5 16924 KOREA, REPUBLIC OF 0 0 1 0 Common Stock 348837 D Common Stock 232558 I By GC Cell Corporation Series A Preferred Stock Common Stock 667185 D Series B Preferred Stock Common Stock 330095 D Series A Preferred Stock Common Stock 292791 I By GC Cell Corporation Series B Preferred Stock Common Stock 62181 I By GC Cell Corporation GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and each disclaims beneficial ownership of all shares held by CG Corp., except to the extent of any pecuniary interest therein. The shares are held directly by GC Cell Corporation. GC Corp., a public Korean holdings company, is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and GC Cell Corporation and each disclaims beneficial ownership of all shares held by such entities, except to the extent of any pecuniary interest therein. Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") is convertible into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering, the Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Preferred Stock has no expiration date. GC Corp By: /s/ Yong-Jun Huh, Chief Executive Officer 2024-07-18 GC Cell Corporation By: /s/ James Park, Chief Executive Officer 2024-07-18